Symlin
(Pramlintide acetate)ApprovedSmall molecule
AstraZenecaPramlintide is used to help people with diabetes (both type 1 and type 2) better control their blood sugar levels by slowing down how quickly food moves through the stomach and reducing the amount of sugar the body produces.[2] Symlin is currently approved and in use across 5 indications[4].[1]
Symlin is one of 141 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
5
Indications
22
Total Trials
0
Active Trials
140
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Symlin
AstraZenecaApproved
Byetta
AstraZenecaPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Sulfonylureas
Eli LillyPreclinical
Acipimox
Boehringer IngelheimPreclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Body Weight3 trials
Type 1 Diabetes3 trials
Type 1 Diabetes Mellitus3 trials
Overweight3 trials
7 more indications
AML2 trials
T1DM1 trial
Type 2 Diabetes Mellitus1 trial
Obese1 trial
MPR1 trial
T2DM1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Symlin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Pramlintide acetate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Amylin Receptor AMY2; CALCR/RAMP2 Agonist; Amylin Receptor AMY3; CALCR/RAMP3 Agonist; Amylin Receptor AMY1, CALCR/RAMP1 Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company